Prostate cancer is the most prevalent non-skin cancer in men and the second leading cause of male cancer death in most high-income countries, occupying a unique position in oncology by virtue of the extraordinary biological diversity it encompasses. At one extreme lies the indolent, low-grade tumor that grows so slowly it will never cause symptoms or shorten life, a biological entity that warrants careful observation but rarely demands immediate treatment. At the other extreme lies the high-grade, rapidly progressive malignancy that metastasizes widely, resists treatment, and produces death within months despite the most aggressive available therapies. Between these poles exists the vast middle ground of intermediate-risk prostate cancer in which the likelihood of lethal progression is meaningful but not certain, and in which the therapeutic decisions of whether, when, and how to treat require careful weighing of oncological risk against the functional consequences of treatment. Understanding and navigating this biological diversity is the central clinical challenge of prostate cancer management.
The detection of prostate cancer was fundamentally altered by the widespread adoption of prostate-specific antigen testing beginning in the 1980s, which produced a dramatic and sustained increase in prostate cancer incidence as large numbers of histologically present but clinically occult tumors were discovered through blood testing. This prostate-specific antigen era has generated both significant benefit, through the detection of genuinely significant tumors at earlier and more curable stages, and significant harm, through the overdiagnosis of indolent tumors that were destined never to cause symptoms and whose detection set in motion diagnostic and therapeutic cascades producing unnecessary morbidity without offsetting oncological benefit. The struggle to maximize the benefits while minimizing the harms of prostate cancer detection has driven decades of research into improved risk stratification tools, better diagnostic approaches, and management strategies that defer active treatment for low-risk disease while ensuring prompt, effective intervention for disease with lethal potential.
The treatment of prostate cancer has been transformed across all stages of the disease by a series of significant therapeutic advances over the past two decades. In the localized setting, refinements in surgical technique and radiation delivery technology have improved functional outcomes while maintaining excellent cancer control. In the metastatic hormone-sensitive setting, combination strategies adding novel hormonal agents or chemotherapy to androgen deprivation therapy have produced substantial survival improvements compared to androgen deprivation alone. In the castration-resistant setting, a succession of new agents targeting the androgen receptor pathway, DNA repair, and the immune system have progressively extended survival. The application of genomic biomarkers to identify patients most likely to benefit from specific treatments has begun to bring precision medicine principles to prostate cancer management.
Anatomy, Physiology and the Role of Androgens
The prostate gland is a walnut-sized exocrine gland of the male reproductive system situated immediately below the bladder and surrounding the proximal urethra, whose primary physiological function is the secretion of prostatic fluid that contributes to the liquid component of semen and supports sperm motility and viability. The gland is divided anatomically into zones including the peripheral zone where the majority of prostate cancers arise, the transition zone where benign prostatic hyperplasia predominates, and the central zone. The prostate gland is entirely dependent on androgen stimulation for its normal development, growth, and function, and this androgen dependence is exploited therapeutically through androgen deprivation therapy that suppresses testosterone to castrate levels, producing the dramatic tumor shrinkage and symptom relief that is the hallmark of the initial hormonal response in metastatic prostate cancer.
Androgens exert their effects on prostate cells through the androgen receptor, a transcription factor that when bound by testosterone or its more potent intraprostatic metabolite dihydrotestosterone, undergoes conformational changes that enable its nuclear translocation and binding to androgen response elements in the promoter regions of androgen-regulated genes. The androgen receptor drives the transcription of genes governing prostate cell proliferation, survival, differentiation, and metabolism, making it the master regulator of prostate gland biology and the central therapeutic target in prostate cancer. The development of castration resistance, in which prostate cancer continues to grow despite medical or surgical castration that suppresses circulating testosterone to castrate levels, reflects the multiple molecular mechanisms through which prostate cancers restore androgen receptor signaling under conditions of androgen deprivation, including androgen receptor gene amplification, ligand-independent androgen receptor activation, androgen receptor splice variant expression, and intratumoral androgen biosynthesis.
Prostate-specific antigen is itself an androgen-regulated gene product, a serine protease secreted by normal and malignant prostate epithelial cells whose concentration in serum reflects the mass of prostate tissue and its degree of androgenic stimulation. In the clinical setting of prostate cancer management, prostate-specific antigen serves multiple important functions: as a screening and detection tool for identifying men who require further evaluation for prostate cancer, as a staging and prognostic factor at diagnosis, as a measure of treatment response following local therapy or the initiation of systemic treatment, and as the earliest detectable indicator of disease recurrence after local treatment through the identification of biochemical recurrence before clinical or radiographic progression becomes apparent.
Active Surveillance and Conservative Management
Active surveillance is the preferred management strategy for men with low-risk prostate cancer and is increasingly recommended for selected men with favorable intermediate-risk disease, offering a pathway to avoid or defer the side effects of definitive local treatment in men whose cancer poses minimal immediate threat to their life expectancy. The biological rationale for active surveillance is grounded in the abundant autopsy data demonstrating that microscopic prostate cancer is extraordinarily common in older men, that the great majority of these cancers grow so slowly that they never progress to clinical significance, and that treatment of the majority of low-grade prostate cancers detected by prostate-specific antigen screening provides no survival benefit while imposing meaningful functional harms.
The key elements of active surveillance protocols include regular monitoring of prostate-specific antigen with defined triggers for concern based on absolute level and rate of change, periodic digital rectal examination to detect clinically apparent changes in the prostate, repeat biopsy at defined intervals or triggered by prostate-specific antigen or clinical changes to detect pathological grade progression, and increasingly, multiparametric magnetic resonance imaging to provide imaging assessment of lesion characteristics and to guide targeted sampling of suspicious areas on repeat biopsy. The long-term outcomes of men managed with active surveillance in prospective cohort studies and clinical trials are excellent, with fifteen-year prostate cancer-specific mortality rates below two to three percent in carefully selected and monitored populations, demonstrating that conservative management with treatment deferred until evidence of significant disease progression is a safe strategy for appropriately selected patients.
The psychological dimensions of active surveillance deserve specific clinical attention, as many men experience significant anxiety about living with a known cancer diagnosis without receiving immediate treatment. The paradox of having cancer and being told that the most appropriate management is watchful waiting runs counter to the deeply ingrained cultural expectation that cancer requires urgent aggressive action, and this cognitive dissonance can be a source of persistent anxiety even in men who intellectually understand the rationale for active surveillance. Proactive psychological support, peer support resources connecting men on active surveillance with others successfully managing their condition conservatively, and clear and consistent communication from the clinical team about the evidence base for active surveillance and the criteria that would trigger transition to active treatment are essential components of comprehensive active surveillance management.
Radical Treatment Modalities for Localized Disease
Men with intermediate and high-risk localized prostate cancer who are candidates for curative-intent treatment face a choice among several treatment modalities that have each demonstrated excellent long-term cancer control rates in appropriately selected patients while producing different patterns of side effects that may differentially affect individual patients based on their baseline functional status and personal priorities. The absence of randomized controlled trial evidence definitively establishing the superiority of any single treatment modality over others for most risk categories means that treatment selection is appropriately guided by shared decision-making in which the patient’s informed preferences are central.
Radical prostatectomy, the surgical removal of the prostate gland and seminal vesicles along with pelvic lymph node dissection in higher-risk cases, provides excellent long-term biochemical recurrence-free survival for localized prostate cancer and offers the advantage of definitive pathological staging that may reveal features warranting adjuvant or salvage treatment. The robotic-assisted laparoscopic approach has become the dominant surgical technique at high-volume centers, providing equivalent oncological outcomes to open surgery with the potential advantages of reduced blood loss, shorter hospital stay, and in experienced hands improved early recovery of urinary continence. The principal long-term side effects of radical prostatectomy are urinary incontinence and erectile dysfunction, whose incidence depends substantially on baseline patient function, surgical technique, and whether nerve-sparing approaches are feasible given tumor location and extent.
External beam radiation therapy has evolved through the development of intensity-modulated radiation therapy, volumetric modulated arc therapy, and image-guided radiation therapy techniques that enable the precise shaping of radiation dose distributions to maximize dose to the prostate while minimizing exposure of the rectum and bladder, reducing toxicity while maintaining tumor control. The escalation of radiation dose to seventy-eight or more Gray, enabled by these advanced delivery techniques, has improved biochemical control rates compared to conventional dose levels. The addition of androgen deprivation therapy to radiation therapy for intermediate and high-risk localized prostate cancer improves biochemical control and overall survival, with the optimal duration of androgen deprivation ranging from six months for favorable intermediate-risk disease to eighteen to thirty-six months for high-risk and locally advanced presentations.
Management of Advanced and Metastatic Disease
The systemic management of metastatic prostate cancer has undergone a revolution over the past decade, transforming from a landscape in which androgen deprivation therapy was the sole available effective systemic treatment for hormone-sensitive disease and docetaxel chemotherapy was the primary option for castration-resistant disease to the current environment of multiple therapeutic classes with proven survival benefits across all stages of advanced disease. This therapeutic expansion reflects both the growing understanding of the molecular mechanisms driving prostate cancer progression and the sustained investment in clinical trial programs that have tested new agents in well-defined patient populations.
For men presenting with newly diagnosed metastatic hormone-sensitive prostate cancer, the treatment paradigm has shifted from androgen deprivation therapy monotherapy to combination strategies that add either docetaxel chemotherapy, abiraterone acetate, enzalutamide, apalutamide, or darolutamide to androgen deprivation therapy, each of which has been demonstrated to significantly improve overall survival in randomized phase III trials. The selection among these intensification options is guided by metastatic burden, patient fitness for chemotherapy, comorbidities, treatment preferences, and cost and access considerations, with all patients being candidates for at least one form of systemic intensification beyond androgen deprivation therapy monotherapy.
The treatment of castration-resistant prostate cancer has benefited from the sequential application of multiple effective therapies including second-generation androgen receptor pathway inhibitors, taxane chemotherapy, radium-223 for bone-predominant disease, poly-ADP ribose polymerase inhibitors for BRCA-mutated disease, and pembrolizumab for mismatch repair-deficient tumors. Germline and somatic genomic testing has become standard practice in the management of metastatic castration-resistant prostate cancer to identify alterations in homologous recombination repair genes including BRCA1, BRCA2, ATM, and CDK12 that predict sensitivity to poly-ADP ribose polymerase inhibitors and to platinum-based chemotherapy regimens, and mismatch repair deficiency that predicts sensitivity to immune checkpoint inhibition. The integration of these precision medicine approaches with the expanding portfolio of effective systemic therapies has produced meaningful improvements in survival for men with advanced prostate cancer over the past decade and established a therapeutic framework that continues to evolve with ongoing clinical research.